VT1093 / Beijing WellGene Biotech - LARVOL DELTA

Phase I Clinical Trial of a Recombinant Oncolytic Virus Injection Combined with PD-1 Antibody-Based Gene Therapy for Recurrent Head and Neck Cancer in China: An Open-Label Study. (PubMed, Virus Res) - "VT1093 shows promising efficacy in controlling disease progression in recurrent head and neck cancer, with a favorable safety profile and low toxicity. These results support further clinical development of VT1093 as a novel therapeutic approach for this patient population."

Journal • P1 data • Fatigue • Gene Therapies • Head and Neck Cancer • Herpes Simplex • Oncology • Solid Tumor

An open-label, dose-escalation phase I clinical trial of intratumoral injection of VT1093 for the treatment of adult patients with recurrent or metastatic malignant solid tumors (ChiCTR) - P1 | N=42 | Completed | Sponsor: Beijing Shijitan Hospital, Capital Medical University; Shanghai Pudong Hospital; Beijing WellGene Biotech Co., Ltd.

New P1 trial • Breast Cancer • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck